Effect of Hyperuricaemia on Chronic Renal Disease

Status Recruiting

Clinical Trial Summary

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

Clinical Trial Description

This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate that low levels of serum uric acid can delay the progression of renal damage. Promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of CKD in patients ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03425708
Study type	Interventional
Source	The Affiliated Hospital of Xuzhou Medical University
Contact	Dong Sun, MD
Phone	15862158578
Email	sundong126@yahoo.com
Status	Recruiting
Phase	Phase 4
Start date	January 1, 2017
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05434858` - Imagery as Biomarker of Gout	N/A
Completed	`NCT04060173` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671	Phase 1
Recruiting	`NCT05504083` - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients	Phase 2
Completed	`NCT04966325` - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects	Early Phase 1
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT00995618` - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia	Phase 2
Completed	`NCT00288158` - Primary Prevention of Hypertension in Obese Adolescents	Phase 2
Terminated	`NCT04987294` - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease	Phase 2
Completed	`NCT04236219` - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers	Phase 1
Completed	`NCT06189404` - Effect of Tigulixostat on the Pharmacokinetics of Theophylline	Phase 1
Recruiting	`NCT05586958` - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients	Phase 3
Recruiting	`NCT06084585` - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia	N/A
Recruiting	`NCT06056570` - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia	Phase 1/Phase 2
Not yet recruiting	`NCT04586803` - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers	Phase 1
Not yet recruiting	`NCT02944214` - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients	N/A
Completed	`NCT02959918` - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid	Phase 2
Completed	`NCT02557126` - Study of URC102 to Assess the Safety and Efficacy in Gout Patients	Phase 2
Active, not recruiting	`NCT01021241` - Safety and Efficacy Study of Intravenous Uricase-PEG 20	Phase 1
Completed	`NCT00756964` - Lowering Serum Uric Acid to Prevent Acute Kidney Injury	Phase 2
Terminated	`NCT00607152` - Rasburicase (Fasturtec) Registration Trial	Phase 3